Promore Pharma
25.10.2021 09:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Stockholm 25 October 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.
In 2020, Promore Pharma completed a clinical trial, HEAL LL-37, a phase IIb double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of a new drug, LL-37 / ropocamptide for local administration in combination with compression therapy. The study was performed on 148 patients suffering from difficult-to-heal venous leg ulcers.
Today, the company announces that a scientific article has been published in the journal Wound Repair and Regeneration, which is the journal of the international society in wound care, Wound Healing Society. Co-authors of the article are several internationally renowned subject area experts, including professors Jan Apelqvist, Arkadiusz Jawien, and Folke Sjöberg.
" We are very content that the results of HEAL LL-37 are now published and available to the scientific community and the general public. The publication is a confirmation of the quality of the completed clinical study ", says Jonas Ekblom, CEO of Promore Pharma.
" Once again, we thank all the staff at the healthcare facilities who have participated in the study for their valuable contributions, " says Margit Mahlapuu, CSO of Promore Pharma.
The published article is entitled "Evaluation of LL-37 in Healing of Hard-to-Heal Venous Leg Ulcers: a Multicentric Prospective Randomized Placebo-Controlled Clinical Trial" and can be read in its entirety via the following link:
https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12977
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/669452/Promore-Pharma-Announces-that-Scientific-Article-has-Been-Published-on-Clinical-Study-Results-with-Ropocamptide-for-Venous-Leg-Ulcers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Surmodics Launches MetalPro(TM) Direct-to-Metal Hydrophilic Coatings for Medical Devices30.10.2026 14:37:00 CET | Press release
HORSHAM, PA / ACCESS Newswire / October 30, 2026 / Surmodics Inc., a leading provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego the launch of MetalPro™ direct-to-metal UV cure hydrophilic coatings engineered to bond directly to metal surfaces without primers or tie-layers. By eliminating additional tie-layers, MetalPro simplifies coating applications, reduces process complexity and has the potential to lower overall coating costs. The direct-to-metal approach also provides manufacturers with greater design flexibility, particularly for complex catheter systems where coating thickness and mechanical performance are important considerations. "Medical device engineers are continually challenged to improve device performance while simplifying manufacturing and managing costs," said Bob Hergenrother, PhD, Vice President of R&D and Innovation a
Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders30.10.2026 14:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / October 30, 2026 / Chervon launches Advanced Momentum Program (AMP), reporting to Matt DeFeo, Senior Vice President, Sales, Training, and Recruiting. Chervon will be hiring hundreds of college graduates in the months and years ahead to deliver the company's aggressive growth strategy. The new AMP initiative was developed to catalyze Chervon's recruiting, training, development, promoting, and mentoring of the very best high-potential college grads. AMP will develop the next generation of Chervon leaders. The program features a comprehensive product, skills, and career development training system. AMP will recruit, develop and promote high-potential new hires into a broad range of positions including store coverage, end-user marketing, sales, product management, e-commerce/digital marketing, channel management, commercialization, service, engineering, supply chain, operations, and finance. Ultimately AMP will produce a stream of outstanding senior execu
Aehr Test Systems Appoints Former Meta Infrastructure Executive Vijay Rao to Board of Directors29.10.2026 12:30:00 CET | Press release
FREMONT, CA / ACCESS Newswire / October 29, 2026 / Aehr Test Systems (NASDAQ:AEHR), a leading provider of test and burn-in solutions for semiconductor devices used in artificial intelligence (AI), silicon photonics, data center, automotive, and industrial applications, today announced the appointment of Vijay Rao to its Board of Directors, effective October 28, 2026. Rao brings 30 years of technology industry experience, including more than 13 years at Meta, where he most recently served as Vice President of Infrastructure. His experience spans infrastructure strategy, AI computing, and semiconductor technologies in hyperscale, enterprise, and startup environments. "Vijay brings deep expertise in infrastructure requirements of hyperscale data centers, including the integration of AI accelerators, high-performance memory, and optical networking," said Gayn Erickson, President and Chief Executive Officer of Aehr Test Systems. "He understands firsthand how semiconductor quality and reliab
U.S. Polo Assn. Executes Early on Europe's Digital Product Passport Mandate29.10.2026 12:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / October 29, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), with a multi-billion-dollar global footprint and distribution in more than 190 countries through some 1,200 U.S. Polo Assn. mono-brand retail stores, numerous branded websites and thousands of other points of distribution worldwide, today announced the brand's early activation of Digital Product Passports (DPPs) across product categories sold into the European Union (EU). As Europe prepares to launch the Digital Product Passport Registry, U.S. Polo Assn. has taken a proactive approach by preparing to deploy DPPs across all products sold into the EU well ahead of the mandatory compliance deadline expected in 2028 or 2029. The global sports brand has already mapped product information for millions of products, creating a scalable framework that will enhance product transparency and support compliance readiness throughout its European operati
LiberNovo Previews Treat Yourself Halloween Flash Sale Across Europe29.10.2026 08:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / October 29, 2026 / LiberNovo is bringing Halloween treats to the desk with its Treat Yourself Halloween Flash Sale, opening October 29 across the European Union and United Kingdom. The event pairs savings of up to 40% on selected Maxis and LiberNovo Omni Pro configurations with limited seasonal gifts for qualifying early shoppers. Spooky extras for your desk Limited Halloween-themed gift packs are available to the first 300 eligible customers in the European Union and the first 100 in the United Kingdom, on a first-come, first-served basis while supplies last. Gift contents, qualifying purchases and availability follow the terms on each regional campaign page. More room for Big and Tall users Maxis is designed around larger frames, with a wider seat and 52 cm seat depth for greater thigh support and room to shift naturally. Maxis Manual provides adjustment by hand. Maxis Electric adds motorised lumbar adjustment and OmniStretch guided back stretching.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom